Brennan L.

Brennan Long is a Partner and Research Analyst specializing in Biotechnology at Hood River Capital Management LLC, where he has been a key member of the investment team since 2018. In this role, he is responsible for fundamental research and investment analysis within the biotechnology sector, supporting the firm’s small- and mid-cap growth equity strategies, with a particular focus on identifying inefficiencies in the healthcare and biotechnology arenas.

Brennan brings over a decade of healthcare investment experience, having previously served as an Equity Research Associate Analyst in Biotechnology at Bloomberg LP and as an Equity Research Associate in Pharmaceuticals at Janney Montgomery Scott LLC. His analytical background and deep sector expertise support Hood River's bottom-up, research-driven approach to portfolio construction, particularly within U.S. and international small-cap growth equity markets.

While specific education data is not publicly available, Brennan is recognized for his specialized knowledge in biotechnology and pharmaceuticals, as well as his consistent contributions to investment research that help inform the firm's recommended positions and asset allocations. His experience spans both the buy-side and sell-side, enhancing Hood River's ability to deliver strong risk-adjusted returns for clients in the life sciences sector.